|
|
Volumn 16, Issue 3, 2009, Pages 287-288
|
|
How effective is natalizumab as second-line treatment for multiple sclerosis in daily clinical praxis?
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BETA1A INTERFERON;
GADOLINIUM;
MITOXANTRONE;
NATALIZUMAB;
PLACEBO;
CLINICAL PRACTICE;
CLINICAL TRIAL;
DRUG EFFICACY;
DRUG SAFETY;
EDITORIAL;
HUMAN;
INFECTION RATE;
MULTIPLE SCLEROSIS;
NUCLEAR MAGNETIC RESONANCE IMAGING;
PRIORITY JOURNAL;
PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY;
RECURRENCE RISK;
RISK REDUCTION;
THERAPY EFFECT;
ANTIBODIES, MONOCLONAL;
CLINICAL TRIALS, PHASE III AS TOPIC;
DRUG THERAPY, COMBINATION;
HUMANS;
IMMUNOLOGIC FACTORS;
INTERFERON-BETA;
MITOXANTRONE;
MULTIPLE SCLEROSIS, RELAPSING-REMITTING;
NEUROPROTECTIVE AGENTS;
RANDOMIZED CONTROLLED TRIALS AS TOPIC;
RECURRENCE;
|
|
EID: 60049083604
PISSN: 13515101
EISSN: 14681331
Source Type: Journal
DOI: 10.1111/j.1468-1331.2008.02518.x Document Type: Editorial |
|
Times cited : (2)
|
|
References (8)
|
